ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bluebird taps Gritstone for oncology cell therapy targets
August 24, 2018Bluebird bio has teamed up with Gritstone Oncology to access another set of targets for its oncology cell therapies. The deal sees Bluebird pay $20 million upfront in return for 10 tumor-specific targets and T-cell receptors (TCRs). -
Bluebird, Gritstone inks deal to develop cancer cell therapies
August 24, 2018Gritstone Oncology will receive $20M in an upfront payment and an additional $10M in the form of a Series C preferred equity investment. -
Bluebird adds targets, $500M in milestones to Medigene TCR pact
May 16, 2018Bluebird bio has added two targets and up to €417 million ($500 million) in milestones to its T-cell receptor (TCR) collaboration with Medigene. -
bluebird backs own CAR-T prospect, takes option to co-develop with Celgene
March 30, 2018Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. -
Ambitious Bluebird Seeks Three Drug Approvals by 2019
January 11, 2018At the J.P. Morgan Healthcare Conference in San Francisco, bluebird bio announced that it expected to file three applications for regulatory approval by the end of 2019 -
Bluebird bio joins the ABPI as a full member
September 15, 2017The Association of the British Pharmaceutical Industry (ABPI) has admitted the American biotech bluebird bio, Inc. as a full member…
Pharma Sources Insight January 2025
